Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open-label, Phase III Trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Open-label, Phase III Trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Anthracyclines; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KAITLIN
  • Sponsors Chugai Pharmaceutical; Roche

    • Most Recent Events

    • 10 Dec 2021 Primary endpoint (Invasive Disease-Free Survival (IDFS) in the Overall Population) has not been met according to the results published in the Journal of Clinical Oncology
    • 10 Dec 2021 Primary results published in the Journal of Clinical Oncology
    • 14 Oct 2021 This trial has been discontinued in Poland (Global end date: 4 June2021).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top